Targeting PML-RARα with retinoids Book Section


Authors: Stein, E. M.; Tallman, M. S.
Editor: Andreeff, M.
Article/Chapter Title: Targeting PML-RARα with retinoids
Title Series: Current Cancer Research
Abstract: All-trans retinoic acid (ATRA), an oral retinoic acid derivative, revolutionized the treatment and prognosis of acute promyelocytic leukemia (APL) and anticipated the current age of targeted cancer therapy. The past 25 years have seen an international effort to design multicenter clinical trials that identify the optimal use of ATRA in patients with APL. Indeed, since ATRA is so effective, contemporary clinical trials aim to de-escalate conventional cytotoxic chemotherapy, as has been the case with other highly curable malignancies such as childhood acute lymphoblastic leukemia and Hodgkin’s lymphoma. In this chapter, we review and reflect upon the seminal clinical trials that have led to the current adoption of ATRA as the standard of care for treating APL. © Springer-Verlag New York 2015. All Rights Reserved.
Keywords: acute promyelocytic leukemia; induction; maintenance; consolidation; all-trans retinoic acid
Book Title: Targeted Therapy of Acute Myeloid Leukemia
ISBN: 978-1-4939-1392-3
Publisher: Springer New York  
Publication Place: New York, NY
Date Published: 2015-01-01
Start Page: 489
End Page: 507
Language: English
DOI: 10.1007/978-1-4939-1393-0_25
PROVIDER: scopus
DOI/URL:
Notes: Book Chapter: 25 -- Target. Therapy of Acute Myeloid Leukemi -- 9781493913930 (ISBN); 9781493913923 (ISBN) -- Part of the series “Current Cancer Research” (2199-2584) -- Export Date: 2 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    344 Stein
  2. Martin Stuart Tallman
    649 Tallman